Moreover, in a review on vitamin D analogues as potential therapeutics in melanoma, the 1,25-dihydroxy-lumisterol, locked in the 6-cis configuration, was cited as a vitamin D analogue which activates the rapid-response pathways and competes with 1α,25-dihydroxyvitamin D3 for MARRS receptor binding, but not for VDR binding43. This evidence concerns the gene VDR and melanoma.